Can you provide the last earnings date for ARS PHARMACEUTICALS INC?
ARS PHARMACEUTICALS INC (SPRY) last reported earnings on 3/9/2026.
ARS PHARMACEUTICALS INC (SPRY) Earnings History & Surprises
NASDAQ:SPRY • US82835W1080
Current stock price
8.05 USD
-0.22 (-2.66%)
At close:
8.05 USD
0 (0%)
After Hours:
SPRY Earnings overview
Past quarterly earnings results for ARS PHARMACEUTICALS INC (SPRY), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Earnings Snapshot
Next Earnings Date
Upcoming- Release Date
- May 12, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.51
- Revenue Estimate
- 23.572M
Last Reported
Most Recent- Release Date
- Mar 9, 2026
- Period
- Q4 / 2025
- EPS Reported
- -$0.42
- EPS Surprise
- 6.77%
- Revenue Surprise
- 7.63%
Beat Rate
Last 8 Quarters 31%
EPS and Revenue beats vs estimates
Quarterly Earnings Historical Results
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | -0.42 | -0.45 | 6.77% | -185.71% | 28.087M | 26.095M | 7.63% | -67.56% |
| Q3 2025 | -0.52 | -0.48 | -8.01% | -160.00% | 32.501M | 29.531M | 10.06% | 1,471.62% |
| Q2 2025 | -0.46 | -0.48 | 4.05% | -253.85% | 15.717M | 14.052M | 11.85% | 3,043.40% |
| Q1 2025 | -0.35 | -0.35 | 1.02% | -218.18% | 7.973M | 7.631M | 4.48% | - |
| Q4 2024 | 0.49 | -0.14 | 443.14% | 800.00% | 86.581M | 16.134M | 436.64% | - |
| Q3 2024 | -0.20 | -0.15 | -32.93% | -25.00% | 2.068M | 586.5K | 252.60% | - |
| Q2 2024 | -0.13 | -0.12 | -9.24% | 27.78% | 500K | 1.02M | -50.98% | 4,900.00% |
| Q1 2024 | -0.11 | -0.11 | 1.96% | 31.25% | - | -100.00% | ||
| Q4 2023 | -0.07 | -0.14 | 50.98% | -109.09% | - | -100.00% | ||
| Q3 2023 | -0.16 | -0.19 | 14.13% | 68.00% | - | - | ||
| Q2 2023 | -0.18 | -0.18 | -1.61% | 67.27% | 10K | - | - | |
| Q1 2023 | -0.16 | -0.17 | 6.45% | 77.14% | 20K | - | - | |
| Q4 2022 | 0.77 | -0.13 | 680.69% | 214.93% | 1.32M | 96.39K | 1,269.44% | - |
| Q3 2022 | -0.50 | -0.36 | -38.08% | 23.08% | - | - | ||
| Q2 2022 | -0.55 | -0.49 | -11.56% | 21.43% | - | - | ||
| Q1 2022 | -0.70 | -0.55 | -28.04% | -29.63% | - | - | ||
| Q4 2021 | -0.67 | -0.72 | 6.43% | 51.09% | - | - | ||
| Q3 2021 | -0.65 | -0.69 | 5.45% | - | - | - | ||
| Q2 2021 | -0.70 | -0.54 | -28.68% | - | - | - | ||
| Q1 2021 | -0.54 | -0.36 | -49.13% | - | - | - | ||
| Q4 2020 | -1.37 | -0.50 | -174.11% | - | - | - | ||
| Q3 2020 | - | - | - | - | ||||
| Q1 2020 | - | - | - | - |
Notes
- EPS and Revenue values are non-GAAP when available, otherwise GAAP.
- Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
- Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
- Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.
Earnings Q2Q Performance Trends
EPS Historical Q2Q growth and Acceleration
Revenue Historical Q2Q growth and Acceleration
Surprise distribution (Last 4 Quarters)
EPS beat statistics
EPS beat (4)
3
Average EPS beat (4)
0.96%
Max EPS beat (4)
6.77%
Min EPS beat (4)
-8.01%
Revenue beat statistics
Revenue beat (4)
4
Average Revenue beat (4)
8.51%
Max Revenue beat (4)
11.85%
Min Revenue beat (4)
4.48%
Analysis
In the last 4 quarters, SPRY has beaten EPS estimates in 3 out of 4 releases
SPRY has consistently beaten revenue estimates in all past 4 earnings releases
In the last 4 quarters, SPRY has beaten the EPS estimates by 1.0% on average.
In the last 4 quarters, SPRY has beaten the revenue estimates by 8.5% on average.
Related analysis
ARS PHARMACEUTICALS INC / SPRY Earnings FAQ
Can you provide information on whether ARS PHARMACEUTICALS INC beat earnings estimates in the last quarter?
ARS PHARMACEUTICALS INC (SPRY) beat EPS estimates and beat revenue estimates in the most recent quarter.
How often does ARS PHARMACEUTICALS INC (SPRY) beat earnings estimates?
In the last 4 quarters, ARS PHARMACEUTICALS INC (SPRY) has beaten EPS estimates in 3 out of 4 releases.